Atnahs

Atnahs is a UK-founded specialty pharmaceutical company focused on lifecycle management of established branded medicines, supplemented by selected in-licensing of novel therapies. The business acquires, develops, commercializes, and re-engineers mature and niche pharmaceutical brands across core areas including cardiovascular disease, endocrinology, neurology, and oncology. Since 2021, Atnahs has operated under the Pharmanovia brand, but the legal entity Atnahs Pharma UK Limited remains active. Its portfolio includes commercial products such as Inderal, Tenormin, Bonviva, Xadago, Sunosi, and oncology/supportive-care assets, and it has added newer partnered products including Ghryvelin, catumaxomab, elamipretide, Reagila, and abaloparatide. The company is private-equity backed, globally commercial in orientation, and acts primarily as a commercial and lifecycle-management pharma rather than a discovery-stage biotech.